"AG1000 could be a significant advancement in women's healthcare and could provide a convenient alternative to progestin-only contraceptive pills," says Symank. "It builds upon Agile's SKINFUSION(TM) technology to create an exciting new option for women who would benefit from progestin-only contraception, such as for breast-feeding mothers and women who should not use estrogen for contraception."
In recognition of the company's outstanding achievements in contraceptive drug development, Frost & Sullivan is proud to present the 2009 North American Pharmaceuticals & Biotechnology Healthcare Innovation Award in Women's Health to Agile Therapeutics, Inc. Each year, Frost & Sullivan presents the Healthcare Innovation Award to the company that has demonstrated a breakthrough approach or degree of differentiation innovation compared to other market participants.
The company's innovative contribution(s) to healthcare make it possible to envision a new level of care in the diagnosis, treatment, and management of disease, leading to better outcomes and quality-of-life for patients. In addition, the company's innovative efforts may also lead to improvements in the tools that clinicians, diagnosticians, researchers, and healthcare administrators have at their disposal to improve quality and efficiency in the provision of healthcare services.
Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved